Form 8-K - Current report:
SEC Accession No. 0001558370-24-010598
Filing Date
2024-08-01
Accepted
2024-08-01 16:10:12
Documents
16
Period of Report
2024-08-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nxtc-20240801x8k.htm   iXBRL 8-K 49307
2 EX-99.1 nxtc-20240801xex99d1.htm EX-99.1 100852
3 GRAPHIC nxtc-20240801xex99d1001.jpg GRAPHIC 6578
  Complete submission text file 0001558370-24-010598.txt   301649

Data Files

Seq Description Document Type Size
4 EX-101.SCH nxtc-20240801.xsd EX-101.SCH 4058
5 EX-101.DEF nxtc-20240801_def.xml EX-101.DEF 2848
6 EX-101.LAB nxtc-20240801_lab.xml EX-101.LAB 17904
7 EX-101.PRE nxtc-20240801_pre.xml EX-101.PRE 11814
18 EXTRACTED XBRL INSTANCE DOCUMENT nxtc-20240801x8k_htm.xml XML 4982
Mailing Address 9000 VIRGINIA MANOR ROAD, SUITE 200 BELTSVILLE MD 20705
Business Address 9000 VIRGINIA MANOR ROAD, SUITE 200 BELTSVILLE MD 20705 240-399-4900
NextCure, Inc. (Filer) CIK: 0001661059 (see all company filings)

EIN.: 475231247 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38905 | Film No.: 241166713
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)